Clinical Trial Search

Primary: Efficacy of Internet-based Program for Increasing Condom Use With Non-main Sex Partners — .68; .56 percentage of sex acts protected by cond

Primary: Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration — 9.91; 14.3; 23.1; 32.4 mg/L

Primary: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Positive (Tumor Proportion Score [TPS] ≥50%) Tumors — 12.3; 10.9 Months — p=0.1276

Primary: Number of Participants With Urine Protein Excretion — 33; 278; 39; 50 Participants

Primary: Change From Baseline in A1C at Week 20 — -0.58; -0.09 Percentage of glycated hemoglobin — p== 0.018

Primary: Enrollment (7 Days) — 29; 126; 88; 145 Participants — p=<.001

Primary: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) — 92; 152; 244; 18 Participants

Primary: Overall Survival — 50; 61; 116; 105 Participants — p=0.18

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…

Primary: Post-operative Pain — 5.47; 4.47; 4.00; 4.28 score on a scale — p=0.24

Primary: Renal Safety Measures — 0; 0; 1 adverse events

Primary: Change in Investigator's Global Assessment Grade — -0.8 units on a scale

Primary: Thermo-evaporative (Schiff Air Blast) Stimuli — 2.188; 2.246; 1.268; 1.811 score on a scale — p=<0.001

Primary: Number of Days Subjects Received Treatment in Each Treatment Arm — 290; 325.3; 369.4; 222.36 Days

Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants